The objective of the study is to assess the tolerance, pharmacokinetic and pharmacodynamic properties of multiple dose adminstration of SHR4640 in healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
48
The South West Hospital
Chongqing, Chongqing Municipality, China
Adverse events
Time frame: Clinical significant changes from baseline up to Day 10
Peak Plasma Concentration(Cmax)(of single dose and at stable status)
Time frame: Up to Day 10
Area under the plasma concentration versus time curve(AUC)(of single dose and at stable status)
Time frame: Up to Day 10
Half-time(T1/2)(of single dose and at stable status)
Time frame: Up to Day 10
Time to the peak plasma concentration(Tmax)(of single dose and at stable status)
Time frame: Up to Day 10
Changes in serum uric acid concentration from baseline
Time frame: Up to Day 10
Changes in urinary uric acid excretion from baseline
Time frame: Up to Day 10
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.